Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives

Bharati Kochar, MD, MSCR,*¶, Yue Jiang, PhD,† Wenli Chen, MS, MA,‡ Yuting Bu, BS,§ Edward L. Barnes, MD, MPH,¶ and Millie D. Long, MD, MPH*

*Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
¶Department of Statistical Science, Duke University, Durham, NC, USA
‡Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
§Department of Statistics, University of North Carolina, Chapel Hill, NC, USA

Address correspondence to: Bharati Kochar, MD, MSCR, Division of Gastroenterology, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA (bkochar@mgh.harvard.edu).

Background: Home infusions (HIs) for biologic medications are an option for inflammatory bowel disease (IBD) patients in the United States. We aimed to describe the population receiving HIs and report patient experience with HIs.

Methods: We conducted a retrospective cohort study in the Quintiles-IMSLegacy PharMetrics Adjudicated Claims Database from 2010 to 2016 to describe the population receiving infliximab (IFX) and vedolizumab (VDZ) HIs and determine predictors for an urgent/emergent visit post-HIs. We then administered a cross-sectional survey to IBD Partners Internet-based cohort participants to assess knowledge and experience with infusions.

Results: We identified claims for 11,892 conventional IFX patients, 1,573 home IFX patients, 4,386 conventional VDZ patients, and 1,383 home VDZ patients. There were no differences in demographics or median charges with IFX home and conventional infusions. Home VDZ infusions had a greater median charge than conventional VDZ infusion. Less than 4% of patients had an urgent/emergent visit post-HIs. Charlson comorbidity index > 0 (odds ratio [OR]: 1.95; 95% confidence interval [CI], 1.01-3.77) and Medicaid (OR: 3.01; 95% CI, 1.53-5.94) conferred significantly higher odds of urgent/emergent visit post-HIs. In IBD Partners, 644 IBD patients responded; 56 received HIs. The majority chose HIs to save time and preferred HIs to conventional infusions. Only 2 patients reported an urgent/emergent visit for HI-related problems.

Conclusions: HI appears to be safe in IBD patients receiving IFX and VDZ. However, patients with fewer resources and more comorbidities are at increased risk for an urgent/emergent visit post-HIs. The overall patient experience with HI is positive. Expansion of HIs may result in decreased therapy-related logistic burden for carefully selected patients.

Lay Summary

Inflammatory bowel disease patients receiving home biologic infusions did not have a greater risk for needing emergent care after their infusion compared with patients receiving healthcare facility-based infusions. Separately, we surveyed patients receiving home infusions and they reported positive experiences.

Key Words: Crohn's disease, ulcerative colitis, inflammatory bowel disease, home infusion, treatment, therapy, home health services, safety

Introduction

The use of biological agents for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) is increasing as the prevalence of inflammatory bowel diseases (IBD) is increasing.1,2 Biological agents constitute the mainstay of treatment for moderate to severe IBD.3,4 Currently, there are 3 classes of biological agents that are commonly used in practice: anti-tumor necrosis factor (TNF) inhibitors, such as infliximab (IFX), anti-integrin inhibitors, such as vedolizumab (VDZ), and an anti-interleukin (IL)-12/IL-23 inhibitor, ustekinumab. Some biological agents require administration intravenously, whereas others are administered subcutaneously.1 Some subcutaneous agents can be administered in a facility, but the majority are administered at home by the patient. Intravenous biologic agents have been traditionally administered in a facility with direct clinician supervision.

Currently, there is a global push to increase care for IBD patients in a home setting.6 IBD is an expensive condition with as much as a third of the cost burden attributed to medications.7 Furthermore, intravenous biologic agents, such as IFX and VDZ, pose a large burden to patients in the form of days missed from work and transportation, among other logistics.5,9 To minimize the burden, home infusions (HIs) of biological agents are now available. Interest in HIs is especially increasing in light of the COVID-19 pandemic. The Crohn's and Colitis Foundation encourages patients to check with their insurers and physicians about HIs.10 However, a formal position statement raises concern about the safety of HIs, likely due to the paucity of available data.11 While the process of receiving HIs varies by payer and region of the country, it typically involves scheduling over the phone, receiving the medication and supplies by mail, and
having a nurse visit in a scheduled time frame to start an intravenous line, collect blood work, administer the medication, and monitor vital signs until the end of the infusion. In the United States, payers are expanding home-based health services as a cost-effective solution, especially for those with chronic conditions. The existing literature, albeit sparse and in small cohorts, demonstrates that HIs of biological agents used to treat IBD may be safe and cost-effective and can result in high patient satisfaction. However, one recent administrative claims-based study concluded that home IFX infusions were associated with suboptimal outcomes. However, safety outcomes were not evaluated in this study.

In order to address the knowledge gap regarding the safety of HIs, we performed a mixed-methods study. We conducted a retrospective cohort study in a large administrative claims database and a separate cross-sectional survey study in an IBD patient-powered research network, IBD Partners (www.ibdpartners.org). In the retrospective cohort, we aimed to describe the population receiving home-based IFX and VDZ infusions across the United States and report safety and charges associated with HIs. In the cross-sectional survey study, we aimed to better understand the patient experience with intravenous biological agents using a large Internet-based cohort of IBD patients that includes patients from every US state.

Methods
We assessed HIs for IBD in 2 ways: through a retrospective cohort study in an administrative claims database and through a cross-sectional study in patients who participate in a large Internet-based cohort of IBD patients.

Retrospective Cohort Study
Data source
We conducted a retrospective cohort study in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database from January 2010 to June 2016. This dataset includes variables that are routinely collected for the purposes of insurance billing such as age, sex, geographic location, prescription medications, international classification of disease (ICD) codes and charges associated with procedures, and other healthcare utilization. Prior research has reported that this database is representative of the national commercially insured population reflecting a variety of demographic factors. This database has been used previously in epidemiological studies of IBD. At the time of this analysis, the database contained enrollment information on over 27 million people across the United States, including nearly 130 million person-years of follow-up data.

Study sample
We included individuals 18 years or older, who have a diagnosis of CD or UC. The diagnosis was defined by those individuals who have at least 2 healthcare contacts on different days with an associated ICD-9 or ICD-10 code for CD or UC. If there are claims for both diagnoses, disease assignment was made based on the majority of the last 9 claims. Previous studies using administrative claims data have defined an IBD disease cohort with this definition.

We stipulated 6 months of continuous enrollment in order to ensure an adequate amount of time to assess charges and determine outcomes. For IFX users, we included all patients from 2010 onward. Since VDZ is a newer agent that was approved for use in 2014, we included patients from May 2014 onward. We used J codes, injection/infusion codes, for IFX and VDZ, to identify IBD patients receiving these infusions. The HI cohort was defined as those who had a code for a home health service on the same day as the index infusion code. The conventional infusion cohorts were those who did not have a code for a home health service on the same day as the index infusion. Cohorts were defined at the time of index infusion.

Outcomes of interest
The primary outcome of interest is emergency department (ED) or urgent care visits in the 2 days following an IFX or VDZ HI. We also described the population receiving HIs and reported charges associated with HIs.

Covariates
Patient demographics such as sex, age, region of the country, and type of IBD were assessed and reported. We evaluated primary payer type; Medicaid insurance status from claims data has been used as a proxy for socioeconomic status in prior work. To include a marker of comorbid illness, selected to be a surrogate for higher health care utilization, we assessed the Charlson comorbidity index (CCI), which has been validated as a marker for comorbid illness in studies using large administrative databases.

Analysis
We constructed a multivariable logistic regression model to determine predictors of an urgent care or ED visit in the 2 days following a HI, adjusting for sex, IBD type, payer, and the CCI. The variables in the model were selected a priori based on clinical judgment; furthermore, these are variables that are often used in similar studies. These analyses were performed using SAS (version 9.3) statistical software (SAS Institute).

Cross-Sectional Survey Study
Separately, we conducted a cross-sectional survey study using the IBD Partners cohort. This is a longitudinal Internet-based cohort of people with IBD. To date, more than 15 000 participants have enrolled from across the United States. In this cohort, more than 4000 participants frequently update their information on the portal and respond to periodic survey questionnaires. In this subgroup of active patients, 25% report currently being on IFX, IFX biosimilar, or VDZ. We designed a short survey instrument for patients receiving IFX and VDZ to assess their knowledge of HI services. Patients completed this survey electronically; a hard copy of the survey with the skip logic detailed is presented in Appendix A. For the patients who receive HI services, we asked about their experience, including reasons why they receive HIs, their preference compared with conventional infusions, and problems they have encountered with HIs. This short survey was included with patients’ baseline or biannual updates from June 2018 to April 2019. The primary data are available through trained data managers at IBD Partners. The Institutional Review Board (IRB) of the University of North Carolina-Chapel Hill, the data management center for IBD Partners, approved this study. We provide a descriptive summary of the results, including quotations from patients when notable. When correlations between patient characteristics and
responses to questions were strong, we performed bivariate analysis to detect significant differences.

**Results**

**Retrospective Cohort Study**

In a retrospective cohort study conducted in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database from January 2010 to June 2016, we identified 11,892 patients who received IFX in a conventional setting and 1,573 patients who received IFX with home health services. CD patients consisted of 70% of the conventional IFX and 68% of the home IFX cohorts. The median age in the conventional IFX group was 45, and 52% were female; the median age in the home IFX group was 44, and 53% were female. The majority of patients in both cohorts had commercial insurance as a primary payer. The median charges for infusions were similar for the conventional IFX and home IFX arms: $5,981 and $6,000, respectively. Of those who received IFX infusions, 3.1% of those in the conventional infusion arm and 2.9% of those in the HI arm had an urgent care or ED visit in the 2 days following an infusion. These results are summarized in Table 1.

In the same database, we identified 438 conventional VDZ users and 138 home VDZ users, between May 2014, when the medication was approved, and June 2016. CD patients consisted of 59% of the conventional VDZ and 67% of the home VDZ cohorts. The median age in the conventional VDZ group was 44, and 56% were female; the median age in the home VDZ group was 45, and 57% were female. In the conventional VDZ arm, 65% had a primary payer that was a commercial insurer and 18% had Medicaid as the primary payer; similarly, in the home VDZ cohort, 82% had a commercial insurance, while 14% had Medicaid as the primary payer. The median charges for conventional VDZ infusion were $7,500, while the median charges for home VDZ infusion were $10,700. Of those who received VDZ infusions, 2.5% of those in the conventional infusion arm and 1.4% of those in the HI arm had an urgent care or ED visit in the 2 days following an infusion. Overall rates of ED/urgent care visits following infusions were significantly higher for patients receiving IFX compared with patients receiving VDZ (3.1% vs 2.2%, $P = .04$).

In a multivariable logistic regression model, the following factors predicted a significantly higher odds for an urgent care or ED visit in the 2 days following a HI: a CCI > 0 (odds ratio [OR]: 1.95; 95% confidence interval [CI], 1.01-3.77) and Medicaid as a primary payer (OR: 3.01; 95% CI, 1.53-5.94). These results are presented in Table 2.

**Cross-Sectional Survey Study**

In a separate survey of participants from the IBD Partners Internet-based cohort, 644 respondents who identified the current use of an infused biologic completed the HI module. Of the respondents, 137 reported receiving infusions at a clinic, 440 received infusions at an infusion center, and 56 reported receiving infusions at home. Characteristics of the population responding to surveys are presented in Table 3. Demographics and disease characteristics were similar between both groups.

Of the 577 patients who do not receive HIs, 54% reported that they would be interested in a HI if that were an option for them. Patients who were interested in HIs were significantly

| Table 1. Characteristics of inflammatory bowel disease patients receiving biologic infusions in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database between January 2010 and June 2016 |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                               | IFX Home infusions | IFX Conventional infusions | VDZ Home infusions | VDZ Conventional infusion |
| N                              | 1573             | 11,892           | 138             | 438             |
| % Crohn’s disease              | 68               | 70               | 67              | 59              |
| % Female                       | 53               | 52               | 57              | 56              |
| Median current age in years (IQR) | 33 (32-59)      | 45 (32-59)      | 45 (33-57)     | 44 (34-57)     |
| Region                         |                  |                  |                 |                 |
| % East                         | 8                | 20               | 5               | 23              |
| % Midwest                      | 20               | 34               | 29              | 43              |
| % South                        | 43               | 30               | 15              | 18              |
| % West                         | 29               | 16               | 51              | 16              |
| Charlson Comorbidity Index     |                  |                  |                 |                 |
| % 0                            | 88               | 90               | 80              | 87              |
| % 1                            | 11               | 9                | 20              | 11              |
| % ≥2                           | 1                | 1                | 0               | 2               |
| Primary payer                  |                  |                  |                 |                 |
| % Commercial                   | 80               | 76               | 82              | 65              |
| % Medicaid                     | 7                | 9                | 14              | 18              |
| % Medicare                     | 2                | 2                | 2               | 1               |
| % Self insured                 | 7                | 7                | 0               | 1               |
| Median charges in US$ (IQR)    | 6000 (3960–10 470) | 5981 (3920–9328) | 10 700 (5364–12 770) | 7500 (6920–11 230) |
| % of ED* visit after infusion  | 2.9              | 3.1              | 1.4             | 2.5             |

Abbreviations: IFX, infliximab; IQR, inter-quartile range; VDZ, vedolizumab.

*Any urgent care or emergency department (ED) visit from the time of infusion up to 2 days after.
Table 2. Adjusted odds of seeking urgent or emergent care after a home infusion for infliximab or vedolizumab in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database between January 2010 and June 2016

|                              | aOR   | 95% CI          |
|------------------------------|-------|-----------------|
| Female                       | 0.85  | (0.49-1.49)     |
| Crohn’s disease              | 0.94  | (0.51-1.75)     |
| CCI >0                       | 1.95  | (1.01-3.77)     |
| Commercial                   | Referent |              |
| Medicaid                     | 3.01  | (1.53-5.94)     |
| Medicare                     | 0.76  | (0.10-5.68)     |

Abbreviations: aOR, adjusted odds ratio; CCI, Charlson Comorbidity Index; CI, confidence interval; IBD, inflammatory bowel disease. *ORs are adjusted for sex, IBD type, CCI, and payer.

younger than those who reported no interest in HIs (44 vs 48 years, \( P = .03 \)). The most common reasons for interest in HIs were that it may save time and be less disruptive to a normal schedule (39%), ease and comfort of being at home (36%), and transportation issues (11%) (Figure 1). Two patients also wrote in that they were interested in HIs due to ease of childcare logistics. Of those who do not receive a HI, 28% reported that they would not be interested in a HI if it were available to them. The most commonly cited reason for no interest was having concerns about getting intravenous (IV) access (32% of respondents). Concerns about safety (15%) and concerns about privacy (15%) were other leading reasons for not wanting a HI. Many patients reported that they liked going to an infusion center: “I like going to an infusion room at the clinic every 8 weeks! I see my favorite nurses and get to relax in a quiet environment for a couple of hours” one patient wrote. Others felt that a HI would be a reflection of “feel[ing] like a homebound patient.” Another patient wrote “seems inefficient (I live in a rural area) for provider and unnecessary for me as I am mostly healthy and can travel to clinic.”

Of the 56 patients who had received a HI, 45% reported that they have a HI because their insurance company requires that it, 39% reported that they chose to receive it at home, and 16% reported that their doctor recommended it. The most common reason that people chose to receive a HI was that it saved time and was less disruptive to their schedule (59%). One patient reported that they chose HIs because they could not get days off from work and another person chose HIs because it was cheaper for them. One patient wrote: “I…have a very complicated, very strict schedule…for home infusions, you schedule the appointment for a specific day, but not a time slot and they don’t call you until the day before to tell you what times are available. That doesn’t work for me and I have had to reschedule appointments because of this, usually logistical problems—difficulty getting the medication delivered from the pharmacy, difficulty scheduling with a home health nurse

Nurse was inexperienced in home infusions and was unable to figure out the infusion pump

Of the patients who reported having a problem with a HI, only 2 patients reported having an urgent care or ED visit for a problem related to the HI.

|                              | Home infusions | Conventional infusions |
|------------------------------|----------------|------------------------|
| N                            | 56             | 577                    |
| Median current age in years (IQR) | 39 (32-48)    | 44 (33-58)             |
| % Crohn’s disease            | 66             | 65                     |
| % Female                     | 80             | 73                     |
| % White                      | 93             | 95                     |
| % ≥College                   | 73             | 77                     |
| % Infliximab                 | 64             | 63                     |
| Median disease duration in years (IQR) | 13 (8-21)    | 14 (8-23)              |
| % History of IBD hospitalization | 70             | 65                     |
| % History of IBD surgery     | 34             | 38                     |
| Median SCCAI (IQR)           | 1 (0-2)        | 2 (1-3)                |
| Median sCDAI (IQR)           | 139 (93-184)   | 93 (58-156)            |

Concomitant IBD medications

- % Oral steroids 0 6
- % Oral mesalamine 16 18
- % Immunomodulators 25 27

Abbreviations: IBD, inflammatory bowel disease; IQR, inter-quartile range; SCCAI, Simple Clinical Colitis Activity Index; sCDAI, Short Crohn’s Disease Activity Index.

Discussion

In our mixed-methods study of HIs for biologic agents used to treat IBD in the United States, we found that HIs were not associated with an increase in subsequent urgent care or ED visits. Having a CCI greater than 0 or having Medicaid as a primary payer conferred significantly higher odds for urgent care/ED visits after HI. These factors could be considered by physicians to help guide infusion location choice for individual patients. However, without specific data on the cause of urgent care/ED visit, it is unknown whether a hospital- or clinic-based infusion location would alter or prevent these complications. In our survey study, the majority of patients who received HI preferred HIs to infusions in a conventional setting. A minority of patients who received HIs reported a problem with it. More than half of patients who received infusions in a conventional setting were potentially interested in receiving HIs.

I...have a very complicated, very strict schedule...for home infusions, you schedule the appointment for a specific day, but not a time slot and they don’t call you until the day before to tell you what times are available. That doesn’t work for me and I have had to reschedule appointments because of this, usually logistical problems—difficulty getting the medication delivered from the pharmacy, difficulty scheduling with a home health nurse

Nurse was inexperienced in home infusions and was unable to figure out the infusion pump

Of the patients who reported having a problem with a HI, only 2 patients reported having an urgent care or ED visit for a problem related to the HI.
A prior study of modality preference for anti-TNF agents concluded that the majority of patients with IBD preferred subcutaneous anti-TNF agents to the intravenous option (IFX). A follow-up study prospectively investigating the reasons behind this finding reported that IFX often required that patients take a day off work as they were spending a median of 6.5 hours out of their house for an infusion. This clearly poses a large burden of disability to IBD patients requiring IFX. Many of our survey respondents cited transportation-related issues as a reason to be interested in HIs. As the number of therapeutic agents available to treat IBD is rapidly expanding, it is also important to better understand the various options for medication administration available to our patients.

In contrast to a published report of 69 patients receiving HIs through the Mt. Sinai IBD Center in New York City, we did not find an increased risk of adverse events in those receiving HIs. In the Mt. Sinai study, 2/3 of patients received IFX infusions. In our study, we found a significantly higher rate of urgent and emergent visits after all IFX infusions, regardless of location, compared with VDZ infusions (3.1% vs 2.2%). Therefore, the higher rate of IFX infusions in the Mt. Sinai cohort may explain the disparate findings. Our study reports on the experience of HIs in 2 separate cohorts across the United States in various practice settings and geographic locations. Furthermore, both factors we identified as conferring a significantly higher risk for an urgent care or ED visit after HI have been reported to increase healthcare utilization in general.

Interestingly, a retrospective chart review performed by an infusion company concluded that fewer than 1% of home IFX infusions for IBD patients resulted in an infusion reaction requiring an ED visit or discontinuation of infusion. Therefore, it is possible that the findings from the Mt. Sinai study are due to the complex nature of patients seen at a tertiary care center. Certainly, there is a possibility of selection bias in our study as well, where the higher-risk patients could be receiving infusions at a center, thereby making rates of ED or urgent care visits in the 2 days following an infusion similar across groups. This speaks to the need to continue to have options for both clinic/hospital-based infusions and HIs for IBD patients with ability for patient and provider input on the selection of infusion location.

Similar to our study, a prior study of IFX HIs in a small cohort of pediatric IBD patients concluded that HIs were safe and preferred by patients and families. A more recent European study of home IFX infusion in 13 adults also reported high patient satisfaction with HIs. In both studies, patients receiving home IFX infusions were carefully selected by clinicians. Again, this is most likely the key to success for HIs: allowing clinicians to select patients who have a preference for and would be good candidates for HIs.

Insurers often cite lower healthcare costs as a reason to encourage HIs. Our findings demonstrate that median charges did not differ dramatically between the home and conventional infusion groups. Another recent claims-based study of HIs supports this finding as well. In fact, home VDZ infusions incurred higher median charges than conventional VDZ infusions. Given the nature of claims-based data, we are not able to provide the actual costs incurred; however, further work to understand associated costs would be beneficial to inform policies for utilization of home health infusions in patients with IBD.

We also identified themes in patient perspectives regarding HIs. A number of patients felt that HIs implied being homebound. Some patients thought that a HI meant that they had to infuse the medication themselves. Other patients voiced concerns that it was unsafe to receive such potent medications at home. A large number of patients reported liking the experience of an infusion center or clinic, including the social aspect of it. Understanding patient perspectives and concerns regarding HIs will help clinicians and insurers better explain HIs to patients.

There are several strengths to our study. We included a large cohort of IBD patients from geographically diverse settings across the United States, which lends to generalizability of our results. Including patient-reported outcomes and anecdotes about their experience with HI adds a qualitative perspective. Our study certainly has limitations. Using administrative claims data does not allow for assessment of disease activity and other such factors that may have a role in the success and safety of infusions. As noted, we only have data for charges and not actual costs incurred. Furthermore, this study is not powered to detect safety. Given the rarity events, we cannot provide granular details on reasons for urgent/emergent visits. Despite these limitations, this is a novel study comparing home and conventional infusions for biologic agents used in the treatment of IBD in the United States.

We found that home IFX and VDZ infusions are safe without an increase in urgent care or ED visits following infusions. Patients with a CCI greater than 0 and those who had Medicaid as a primary payer had significantly higher odds of an urgent care or ED visit following an infusion. The majority of patients who receive HIs are satisfied with the experience. Over half of the patients not currently receiving HI reported an interest in HIs, particularly younger patients. These data can help both clinicians caring for IBD patients and payers provide patient-centered care among individuals receiving infusion-based therapies.

**Supplementary Data**

Supplementary data are available at Crohn’s and Colitis 360 online.
Funding
This work was supported by grants from the National Institutes of Health [P30DK034987] and the Crohn's and Colitis Foundation [568735 (B.K.)] and 567497 (E.L.B.)].

Author Contributions
B.K.: study concept and design, analysis and interpretation of data, drafting of manuscript, and obtained funding; Y.J.: acquisition of data, analysis and interpretation of data, and critical revision of manuscript; W.C.: acquisition of data, analysis and interpretation of data, and critical revision of manuscript; Y.B.: analysis and interpretation of data; E.L.B.: study concept and design and critical revision of manuscript; M.D.L.: study concept and design, acquisition of data, critical revision of manuscript, and study supervision.

Conflicts of Interest
B.K.: No personal conflicts of interest, but potential financial conflict of interest having served on an advisory board for Pfizer, Inc.; Y.J.: No personal or financial conflicts of interest; W.C.: No personal or financial conflicts of interest; Y.B.: No personal or financial conflicts of interest; E.L.B.: No personal conflicts of interests, but the following potential financial conflicts of interest due to consulting for AbbVie, Gilead, Pfizer, Takeda, and Target RWE; M.D.L.: No personal conflicts of interests, but the following potential financial conflicts of interest due to consulting for Takeda, Pfizer, AbbVie, Janssen, UCB, Prometheus, Salix, Valeant, and Target Pharmasolutions, and grant support from Takeda and Pfizer.

Data Availability
The claims data are from the IMS Health Real-World Data Adjudicated Claims database (now PharMetrics Plus), which are not publically available; the study authors have obtained the data under a prior data use agreement from the data source. The study authors have obtained the claims data from the IMS Health Real-World Data Pharmasolutions, and grant support from Takeda and Pfizer.

Reference
1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517.

2. Shivashankar R, Tremaine WJ, Harmsen WS, Lofrus EV Jr. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–863.

3. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1459–1463.

4. Bessler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058.e3.

5. Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088–1103.

6. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–968.

7. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–1913.

8. Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18(8):1523–1530.

9. Buisson A, Seigle AL, D’huart MC, et al. The extra burden of infiximab infusions in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(11):2464–2467.

10. Foundation CasC. National Scientific Advisory Committee. COVID-19 & IBD Medication. Crohn’s & Colitis Foundation; 2020. Accessed January 7, 2020. https://www.crohnscolitisfoundation.org/coronavirus/ibd-medication

11. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159(1):350–357.

12. Luke J. Why hospitals and payers are recommending home care upon discharge instead of SNF or traditional home health services—alternative payment model hospital incentives aligning with patient choice. World Hosp Health Serv. 2016;52(1):33–36.

13. Condino AA, Fidanza S, Hoffenberg EJ. A home infiximab infusion program. J Pediatr Gastroenterol Nutr. 2005;40(1):67–69.

14. Kuin S, Stolte SB, van den Brink GR, et al. Short Article: Remicade infusions at home: an alternative setting of infiximab therapy for patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2016;28(2):222–225.

15. Giese-Kim N, Wu M, Dehghan M, et al. Home infiximab infusions are associated with suboptimal outcomes without cost savings in inflammatory bowel diseases. Am J Gastroenterol. 2020;115(10):1698–1706.

16. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95(3):227–234.

17. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–248.

18. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268–274.

19. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–1429.

20. Long MD, Farrey FA, Okafor PN, et al. Increased risk of Pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(5):1018–1024.

21. Crockett SD, Hansen RA, Sturmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18(6):1048–1056.

22. Lin KK, Sewell JL. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108(12):1824–1830.

23. Charlson M, Wells MT, Ullman R, et al. The Charlson Comorbidity Index can be used prospectively to identify patients who will incur high future costs. Plos One. 2014;9(9):e112479.

24. Deyo RA, Cherkin DC, Gol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.

25. Fenster M, Ungaro RC, Hirten R, et al. Home vs hospital infusion of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(1):257–258.

26. Axelfred JE, Sharma R, Laszkowska M, et al. Increased health-care utilization by patients with inflammatory bowel disease covered by Medicaid at a tertiary care center. Inflamm Bowel Dis. 2019;25(10):1711–1717.

27. Checkley LA, Kristofek L, Kile S, Bolgar W. Incidence and management of infusion reactions to infiximab in an alternate care setting. Dig Dis Sci. 2019;64(3):855–862.